{
    "clinical_study": {
        "@rank": "87484", 
        "arm_group": {
            "arm_group_label": "TriGuard\u2122HDH", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergoing TAVR will be treated wIth experimental device TriGuard\u2122HDH"
        }, 
        "brief_summary": {
            "textblock": "Pilot study enrolling up to 12 patients at a single investigational site in the Netherlands.\n      Patients for TAVR will be enrolled to receive the Embolic Deflection Device throughout the\n      duration of the TAVR procedure."
        }, 
        "brief_title": "DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard\u2122HDH in Patients Undergoing TAVR", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Valve Stenosis", 
        "condition_browse": {
            "mesh_term": "Aortic Valve Stenosis"
        }, 
        "detailed_description": {
            "textblock": "Prospective, single center, single arm pilot study enrolling up to 12 patients at a single\n      investigational site in the netherlands. Patients meeting eligibility criteria for TAVR and\n      none of the exclusion criteria will be enrolled to receive the Embolic Deflection Device\n      throughout the duration of the TAVR procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The patient must be \u2265 18 years of age.\n\n          2. The patient meets indications for transcatheter aortic valve replacement procedure.\n\n          3. The patient is willing to comply with specified follow-up evaluations.\n\n          4. The patient, or legally authorized representative, has been informed of the nature of\n             the study, agrees to its provisions and has been provided written informed consent,\n             approved by the appropriate Medical Ethics Committee (EC).\n\n        Exclusion Criteria:\n\n          1. Patients undergoing transcatheter aortic valve replacement via the trans-axillary,\n             subclavian, or direct aortic route\n\n          2. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year\n             following index procedure. Female subjects of child-bearing potential must have a\n             negative pregnancy test done within 7 days prior to index procedure per site standard\n             test.\n\n          3. Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours\n             preceding the index procedure (according to definition) or AMI > 72 hours preceding\n             the index procedure and creatine kinase and creatine kinase fraction have not\n             returned to normal limits at the time of procedure.\n\n          4. Patients who are currently experiencing clinical symptoms consistent with new onset\n             AMI, such as nitrate-unresponsive prolonged chest pain.\n\n          5. Patients with impaired renal function (estimated Glomerular Filtration Rate\n             [Estimated Glomerular Filtration Rate] <30, calculated from serum creatinine by the\n             Cockcroft-Gault formula).\n\n          6. Patients with torturous/unsuitable anatomy as related to major cerebral arteries in\n             the aortic arch that may interfere with device deployment or remain deployed.\n\n          7. Patients with a platelet count <100.000 cells/mm\u00b3 or >700.000 cells/mm\u00b3 or a white\n             blood cell <3000 cells/mm\u00b3 within 7 days prior to index procedure.\n\n          8. Patients with a history of bleeding diathesis or coagulopathy or patients in whom\n             anti-platelet and/or anticoagulant therapy is contraindicated, or will refuse\n             transfusion.\n\n          9. Patients who have received any organ transplant or are on a waiting list for any\n             organ transplant.\n\n         10. Poor fluoroscopic visualization due to obesity or other medical reason\n\n         11. Hypotension requiring iv/ia medication or other therapy such as resuscitation and\n             defibrillation\n\n         12. Patients with known other medical illness or known history of substance abuse that\n             may cause non-compliance with the protocol, confound the data interpretation or is\n             associated with a life expectancy of less than one year.\n\n         13. Patients with a known hypersensitivity or contraindication to aspirin,\n             heparin/bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, latex,\n             and/or contrast sensitivity that cannot be adequately pre-medicated.\n\n         14. Patients with a history of a stroke or transient ischemic attack (TIA) within the\n             prior 6 months.\n\n         15. Patients with an active peptic ulcer or upper gastrointestinal (GI) bleeding within\n             the prior 6 months.\n\n         16. Patients presenting with cardiogenic shock.\n\n         17. Patients with severe peripheral arterial disease that precludes the delivery sheath\n             vascular access.\n\n         18. Patients with severe calcification/atheroma, friable or mobile atherosclerotic plaque\n             in the aortic arch\n\n         19. Patients with contraindication to cerebral MRI.\n\n         20. Patients going through unprotected (cerebral embolization) cardiovascular procedure\n             prior, during or post transcatheter aortic valve replacement procedure, before the\n             post-procedure diffusion-weighted magnetic resonance imaging evaluation\n\n         21. Patients who have a planned treatment with any other investigational device or\n             procedure during the study period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073851", 
            "org_study_id": "DEFLECT II"
        }, 
        "intervention": {
            "arm_group_label": "TriGuard\u2122HDH", 
            "description": "TriGuard\u2122HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)", 
            "intervention_name": "TriGuard\u2122HDH", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "TAVR", 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "contact": {
                "email": "P.Stella@umcutrecht.nl", 
                "last_name": "Pieter Stella, Md.", 
                "phone": "+31 (0)88 75 59452"
            }, 
            "facility": {
                "address": {
                    "city": "Utrecht", 
                    "country": "Netherlands"
                }, 
                "name": "UMC Utrecht"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Single Arm Feasibility Pilot Study to Evaluate the Safety and Performance of the TriGuard\u2122HDH Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)", 
        "overall_contact": {
            "email": "P.Stella@umcutrecht.nl", 
            "last_name": "Pieter Stella, Md.", 
            "phone": "+31 (0)88 75 59452"
        }, 
        "overall_official": {
            "affiliation": "UMC Utrecht", 
            "last_name": "Pieter Stella, Md.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: Ministry of Health, Welfare and Sport", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Device performance will be evaluated for the following functions: Access the aortic arch, Deploy the TriGuard\u2122HDH from the delivery catheter, Position the TriGuard\u2122HDH to cover the cerebral/carotid vessels, Retrieve the TriGuard\u2122HDH system intact", 
            "measure": "Device performance", 
            "safety_issue": "No", 
            "time_frame": "During TAVR procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073851"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The number of new cerebral lesions by diffusion-weighted MRI one week post procedure", 
                "measure": "Number of new cerebral lesions", 
                "safety_issue": "No", 
                "time_frame": "one week post procedure"
            }, 
            {
                "description": "The volume of new cerebral lesions by diffusion weighted MRI one week post procedure", 
                "measure": "Volume of new cerebral lesions", 
                "safety_issue": "No", 
                "time_frame": "One week post procedure"
            }
        ], 
        "source": "Keystone Heart", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Keystone Heart", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}